Clinical Trials & Research

A new study by researchers in the Netherlands and published on the preprint server bioRxiv* in June 2020 describes the differences in T and B cell responses seen in patients with severe COVID-19. The current pandemic of COVID-19 caused by the RNA virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has by now, in just

Print this page London, UK June 19, 2020 – GSK’s scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine has entered into human clinical trials. Clover today announced the initiation of a Phase 1 clinical study evaluating the company’s COVID-19 S-Trimer vaccine (SCB-2019) in combination with GSKs pandemic adjuvant system.  The study initiation follows

Reviewed by Emily Henderson, B.Sc.Jun 18 2020 When some species are heavily hunted, animal mortality increases and they have fewer offspring in the course of their lives. To compensate for this, animals that are hunted often respond by becoming sexually mature and bearing young earlier than species that are not hunted. In other words, animals

Print this page INDIANAPOLIS, June 15, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the first patient has been enrolled in a Phase 3 randomized, double-blind, placebo–controlled study to evaluate the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licensed from Incyte, in hospitalized adults with COVID-19. Baricitinib, marketed as

Reviewed by Emily Henderson, B.Sc.Jun 16 2020 A new study co-led by Simon Fraser University health sciences professor Scott Lear provides further evidence of the link between depressive symptoms and an increased risk of heart disease and early death. The global study tracked 145,862 middle-aged participants from 21 countries and found a 20 per cent

Print this page June 13, 2020 — AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by the end of 2020. With today’s agreement, the IVA aims to

Reviewed by Emily Henderson, B.Sc.Jun 12 2020 Scientists at RCSI University of Medicine and Health Sciences have developed a new biomaterial that has the potential to accelerate bone regeneration by promoting an immune response that encourages repair and lowers the risk of inflammation. The study, conducted by researchers at RCSI Tissue Engineering Research Group (TERG)

Print this page TARRYTOWN, N.Y., June 11, 2020 /PRNewswire/ – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Science has accepted for publication two papers describing the creation of its novel two-antibody cocktail, REGN-COV2, and its potential to diminish risk of viral escape by effectively binding to the virus’s critical spike protein in two separate, non-overlapping locations. The publications will be available

A new study finds that proposal to create a “microbial Noah’s ark” to protect the long-term health of humanity is feasible and should move forward into a pilot project phase, that would include installing infrastructure to store microbes in a site such as Norway or Switzerland and a collaboration for collecting samples all over the

Jun 11 2020 Thought LeadersProf. Carsten WelschHead of the Physics DepartmentUniversity of Liverpool How does radiotherapy work? Radiotherapy is a method of treating cancer using radiation. In principle, radiotherapy could use all types of radiation but the most common types are X-rays and electron beams. Less well-known and less commonly used is high energy proton

Print this page INDIANAPOLIS, June 8, 2020 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) announced today its partner Junshi Biosciences (HKEX: 1877) has dosed the first healthy volunteer in a study of a potential neutralizing antibody treatment designed to fight COVID-19. The investigational medicine, referred to as JS016, is being co-developed by Junshi Biosciences and Lilly, with

Jun 9 2020 Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased to announce that a BAMS™ (bead-assisted mass spectrometry) diagnostic test for the COVID-19 infection, being developed with its partner Adeptrix (Beverly MA, USA), has reached the prototype stage and can detect the coronavirus spike protein in model samples

Print this page FOSTER CITY, Calif.–(BUSINESS WIRE)–May 29, 2020– Gilead Sciences, Inc. (Nasdaq: GILD) today announced updated results from a single-arm, open-label Phase 1b trial of magrolimab, an investigational anti-CD47 monoclonal antibody, in combination with azacitidine in previously untreated patients with higher-risk myelodysplastic syndrome (MDS) and previously untreated patients with acute myeloid leukemia (AML) who are ineligible

Reviewed by Emily Henderson, B.Sc.Jun 5 2020 Announcing a new article publication for BIO Integration journal https://bio-integration.org/wp-content/uploads/2020/05/bioi20200007.pdf. In this review article the author Almando Geraldi from the Universitas Airlangga, Indonesia considers the advances in the production of minor ginsenosides using microorganisms and their enzymes. In this review, various minor ginsenosides production strategies, namely utilizing microorganisms

Print this page FOSTER CITY, Calif.–(BUSINESS WIRE)–Jun. 1, 2020– Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label study evaluated 5-day and 10-day courses of the investigational antiviral remdesivir plus standard of care, versus standard of care alone. The study demonstrated that

Prior studies have suggested women might have higher mortality of cirrhosis of the liver than men. Women are also less likely to receive liver transplantation. But the research was unclear. A comprehensive new Northwestern Medicine study shows women are not more likely to die of liver cirrhosis than men, demonstrating that this chronic liver disease

Print this page NEW YORK–(BUSINESS WIRE) June 03, 2020 — Pfizer Inc. (NYSE: PFE) announced today that JAMA Dermatology has published complete results from the second Phase 3 monotherapy pivotal study (JADE MONO-2) of abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in patients aged 12 and older with moderate to severe atopic

Interview conducted by Emily Henderson, B.Sc.Jun 3 2020 Thought LeadersDr. Albert RizzoChief Medical OfficerAmerican Lung Association News-Medical speaks to Dr. Albet Rizzo about silent hypoxia and how it is occurring in individuals that are suffering from COVID-19. What is silent hypoxia and how can it occur? Silent hypoxia is when a pulse oximetry check on

Print this page CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 29, 2020– Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the first participants in each age cohort have been dosed in the Company’s Phase 2 study of its mRNA vaccine candidate

Bottom Line: Among patients with both colorectal cancer and diabetes in Korea, those who had a high adherence to their oral diabetes medication had a significantly reduced risk of overall mortality compared with those with lower adherence. Journal in Which the Study was Published: Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association

Print this page KENILWORTH, N.J. & MIAMI–(BUSINESS WIRE) May 26, 2020 –Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics LP, a closely held biotechnology company, today announced that the companies have entered into a collaboration agreement to develop EIDD-2801, an orally available antiviral candidate currently in early clinical

Reviewed by Emily Henderson, B.Sc.May 29 2020 Cameron Nowzari, Assistant Professor, Electrical and Computer Engineering, received $150,000 from the National Science Foundation for a project in which he and his collaborators are developing numerical methods and mathematical models to provide complementary support to the epidemiologists worldwide who are working to understand how COVID-19 spreads. Some

Print this page KENILWORTH, N.J.–(BUSINESS WIRE) May 26, 2020 –Merck (NYSE: MRK), known as MSD outside the United States and Canada, will today announce three significant scientific initiatives to combat COVID-19: two agreements to develop potential vaccines against SARS-CoV-2, and a research collaboration to advance the development of a novel antiviral candidate. Today’s announcements are:

A new study on the frog brain may lead to innovative ways of repairing congenital disabilities in humans. A team of researchers from Tufts University, Universitat de Valencia, and Harvard University has discovered that the brains of developing frog embryos damaged by nicotine exposure can be repaired by using “ionoceuticals” that can help in the

Print this page GAITHERSBURG, Md., May 25, 2020 (GLOBE NEWSWIRE) – Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVX‑CoV2373, a stable, prefusion protein made using its proprietary nanoparticle technology. NVX‑CoV2373 includes Novavax’ proprietary

May 26 2020 Leading PCR and qPCR technology now available for high-throughput applications: With the Biometra TRobot II and qTOWER³ auto, Analytik Jena presents two new thermal cyclers for fully automated PCR and qPCR applications. Both systems follow a modular approach and are designed as open systems. Both devices are particularly robust and were developed

Print this page PHILADELPHIA–(BUSINESS WIRE)–May 14, 2020 — Neuraptive Therapeutics, Inc. (Neuraptive), a clinical-stage biotechnology company dedicated to developing novel therapeutics and medical products for treatment of peripheral nerve injuries (PNI), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its franchise therapeutic product, NTX-001, in the treatment

Reviewed by Emily Henderson, B.Sc.May 22 2020 In complex operations, is there a correlation between the volume of service provided per hospital and the quality of the treatment outcome? This question is addressed in eight commissions on minimum volumes that the Federal Joint Committee (G-BA) has issued to the Institute for Quality and Efficiency in